What happened
Bukwang Pharmaceutical IND filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$32.2M (−0.1% year on year), operating profit of US$759K (−62.6% year on year) and net income of US$794K (from a loss a year earlier).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$32.2M |
|---|---|
| Revenue vs a year earlier | −0.1% |
| Operating profit | US$759K |
| Net income | US$794K |
| Period | Q1 2026 (consolidated) |
| Filed | 2026-04-21, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260421800307 → open original filing |
Source: DART. Information only, not investment advice.